Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country

无容量 医学 中止 四分位间距 内科学 肺癌 肿瘤科 置信区间 回顾性队列研究 癌症 外科 免疫疗法
作者
Mauricio Luján,Mauricio Lema,Beatriz Preciado,Camila Lema,Jorge Egurrola,Andrés F. Cardona,Diego González,William Mantilla,Luís Pino,Gustavo Bueno Rojas,Diego Hernán Arias Gómez,Isabel Munévar,Raimundo Manneh,Ray Manneh Kopp,José Lobatón,Esteban Calle,Mariana Borras Osorio,Iván Triana,P.A. Londoño,Sandra Aruachán
出处
期刊:Journal of Investigative Medicine [SAGE Publishing]
卷期号:71 (5): 502-510 被引量:1
标识
DOI:10.1177/10815589221147897
摘要

Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second-line (2L) or third-line (3L) therapy in patients with advanced NSCLC. This is a multicentric observational study. Data of patients with advanced NSCLC who received nivolumab as 2L or 3L treatment were analyzed retrospectively. Information regarding patient demographics and clinical backgrounds, treatment patterns from diagnosis to post-nivolumab treatment, effectiveness, and safety of nivolumab treatment were collected. The outcomes evaluated were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) to treatment. OS and PFS were estimated with the Kaplan-Meier method and the differences were evaluated through the log-rank test. Data of 178 patients were included. The median follow-up was 26.8 months (interquartile range (IQR): 20.3-40.4). Nivolumab was commonly used as a 2L treatment (77.5%). The outcomes in this setting (2L) were as follows: ORR was 21.0%, and the median PFS and OS were 5.5 months (95% confidence interval (CI): 4.5-6.5) and 12.4 months (95% CI: 10.8-14.0), respectively. In 3L, the ORR with nivolumab was 15.0%, the median PFS and OS were 4.1 months (95% CI: 3.1-5.1) and 10.1 months (95% CI: 9.4-10.6), respectively. Three patients (1.7%) required discontinuation due to toxicity. Nivolumab effectiveness and safety in this scenario was consistent with that reported by previous trials and other real-world data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zhongrui完成签到,获得积分10
刚刚
川川发布了新的文献求助10
刚刚
WYL发布了新的文献求助10
1秒前
酷波er的应助被火星上的幻梦采纳,获得20
2秒前
Angel完成签到,获得积分10
2秒前
3秒前
科研通AI6.3的应助被lmx采纳,获得10
4秒前
一干拉就被秒完成签到 ,获得积分10
4秒前
奋斗瑶完成签到,获得积分10
4秒前
bfs发布了新的文献求助10
5秒前
5秒前
科研通AI6.2的应助被FionaZhang采纳,获得10
6秒前
Forever完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
完美世界的应助被Silent采纳,获得10
7秒前
8秒前
8秒前
lilili关注了科研通微信公众号
8秒前
QDDYR完成签到 ,获得积分10
9秒前
9秒前
WKR完成签到,获得积分10
9秒前
科研通AI6.3的应助被嘿撒采纳,获得10
10秒前
李健的应助被明明采纳,获得10
10秒前
Amanda完成签到,获得积分10
11秒前
12秒前
12秒前
大模型的应助被vavel采纳,获得30
12秒前
简单完成签到,获得积分10
13秒前
13秒前
probiotics完成签到,获得积分10
13秒前
Eric完成签到,获得积分10
13秒前
萧小五发布了新的文献求助10
14秒前
华仔的应助被peiyu采纳,获得10
14秒前
小郭完成签到,获得积分10
15秒前
16秒前
鹿乃发布了新的文献求助10
16秒前
精明的寒天完成签到,获得积分10
16秒前
Oro完成签到,获得积分20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082